PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PolyPid (NASDAQ: PYPD), a late-stage biopharma company focused on improving surgical outcomes, will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025, at the Lotte New York Palace Hotel in New York City.
The company's management will engage in a fireside chat with H.C. Wainwright Managing Director Brandon Folkes on Monday, September 8, from 11:30 AM to 12:00 PM ET. Additionally, the management team will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via meetings@hcwco.com.
PolyPid (NASDAQ: PYPD), società biofarmaceutica in fase avanzata dedicata a migliorare gli esiti chirurgici, parteciperà al 27° Annual H.C. Wainwright Global Investment Conference l’8 e il 9 settembre 2025 presso il Lotte New York Palace Hotel di New York City.
La direzione terrà un fireside chat con il Managing Director di H.C. Wainwright, Brandon Folkes, lunedì 8 settembre dalle 11:30 alle 12:00 ET. Inoltre, il team dirigenziale sarà disponibile per incontri individuali con gli investitori, prenotabili tramite i rappresentanti di H.C. Wainwright o scrivendo a meetings@hcwco.com.
PolyPid (NASDAQ: PYPD), una compañía biofarmacéutica en fase avanzada centrada en mejorar los resultados quirúrgicos, participará en la 27ª Conferencia Anual Global de Inversiones H.C. Wainwright los días 8 y 9 de septiembre de 2025 en el Lotte New York Palace Hotel de Nueva York.
La dirección mantendrá un fireside chat con el Managing Director de H.C. Wainwright, Brandon Folkes, el lunes 8 de septiembre de 11:30 a 12:00 ET. Además, el equipo directivo estará disponible para reuniones uno a uno con inversores, que pueden coordinarse a través de los representantes de H.C. Wainwright o enviando un correo a meetings@hcwco.com.
PolyPid (NASDAQ: PYPD), 수술 결과 개선에 주력하는 후기 단계 바이오제약사로서 2025년 9월 8~9일 뉴욕 롯데 뉴욕 팰리스 호텔에서 열리는 제27회 연례 H.C. Wainwright 글로벌 투자 컨퍼런스에 참가합니다.
경영진은 9월 8일 월요일 동부시간 오전 11시 30분부터 12시까지 H.C. Wainwright의 매니징 디렉터 Brandon Folkes와 파이어사이드 챗을 진행합니다. 또한 경영팀은 투자자들과의 1:1 미팅을 진행할 예정이며, H.C. Wainwright 담당자 또는 meetings@hcwco.com을 통해 예약할 수 있습니다.
PolyPid (NASDAQ: PYPD), une société biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, participera à la 27e conférence annuelle mondiale H.C. Wainwright les 8 et 9 septembre 2025 au Lotte New York Palace Hotel à New York.
La direction prendra part à un fireside chat avec le Managing Director de H.C. Wainwright, Brandon Folkes, le lundi 8 septembre de 11h30 à 12h00 ET. De plus, l'équipe de direction sera disponible pour des rencontres individuelles avec des investisseurs, qui peuvent être organisées via les représentants de H.C. Wainwright ou à l'adresse meetings@hcwco.com.
PolyPid (NASDAQ: PYPD), ein Biopharmaunternehmen in der späten Entwicklungsphase, das sich auf die Verbesserung chirurgischer Ergebnisse konzentriert, wird an der 27. jährlichen H.C. Wainwright Global Investment Conference am 8. und 9. September 2025 im Lotte New York Palace Hotel in New York City teilnehmen.
Das Management wird am Montag, dem 8. September, von 11:30 bis 12:00 Uhr ET ein Fireside Chat mit H.C. Wainwright Managing Director Brandon Folkes führen. Zusätzlich steht das Managementteam für Einzelgespräche mit Investoren zur Verfügung, die über Vertreter von H.C. Wainwright oder via meetings@hcwco.com vereinbart werden können.
- None.
- None.
PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.
PolyPid's fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, will take place from 11:30 AM - 12:00 PM ET on Monday, September 8, 2025.
The PolyPid management team will participate in virtual and in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with PolyPid through their H.C. Wainwright representative or e-mail meetings@hcwco.com.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
polypid@arxadvisory.com
FAQ
When is PolyPid (PYPD) presenting at the H.C. Wainwright Conference 2025?
How can investors schedule meetings with PolyPid management at the H.C. Wainwright Conference?
Where is the 2025 H.C. Wainwright Global Investment Conference being held?
What type of company is PolyPid (PYPD)?
